Room C3.3
Presenter
Mechanisms and management of AMR in kidney transplant recipients
Lecture
Prolonged CD38 targeting with felzartamab achieves sustained suppression of antibody-mediated rejection in kidney transplant recipients: a biomarker-guided open-label phase 2 extension